The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
CD47 expression patterns in thymic epithelial tumors.
 
Thomas Yang Sun
No Relationships to Disclose
 
Brandon Nguyen
No Relationships to Disclose
 
Simon Chen
No Relationships to Disclose
 
Yasodha Natkunam
No Relationships to Disclose
 
Sukhmani Kaur Padda
Honoraria - CME Solutions; Janssen; Jazz Pharmaceuticals; MECC Global Meetings; Medical Oncology Association of Southern California; Nanobiotix; Physicans' Education Resource
Consulting or Advisory Role - AstraZeneca; AstraZeneca; Blueprint Medicines; G1 Therapeutics; Genentech; Genzyme; Janssen Oncology; Jazz Pharmaceuticals; Mirati Therapeutics
Research Funding - Bayer (Inst); BioAtla (Inst); Boehringer Ingelheim (Inst); EpicentRx (Inst)
Other Relationship - OncLive/MJH Life Sciences
 
Matt Van De Rijn
No Relationships to Disclose
 
Heather A. Wakelee
Consulting or Advisory Role - AstraZeneca; Blueprint Medicines; Mirati Therapeutics
Research Funding - ACEA Biosciences (Inst); Arrys Therapeutics (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Clovis Oncology (Inst); Genentech/Roche (Inst); Helsinn Therapeutics (Inst); Merck (Inst); Novartis (Inst); Seagen (Inst); Xcovery (Inst)
(OPTIONAL) Uncompensated Relationships - Genentech/Roche; Merck
 
Jonathan W. Riess
Consulting or Advisory Role - BeiGene; Blueprint Medicines; Boehringer Ingelheim; Bristol-Myers Squibb/Celgene; Daiichi Sankyo; EMD Serono; Genentech; Janssen Oncology; Jazz Pharmaceuticals; Novartis; Regeneron; Teladoc; Turning Point Therapeutics
Research Funding - AstraZeneca/MedImmune (Inst); Boehringer Ingelheim (Inst); GlaxoSmithKline (Inst); Merck (Inst); Novartis (Inst); Revolution Medicines (Inst); Spectrum Pharmaceuticals (Inst)